LakeShore Biopharma Co Ltd. is engaged in discovering, developing, manufacturing, and marketing of vaccines.
LakeShore Biopharma Co., Ltd is a dynamic biopharmaceutical firm specializing in the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics. Focused on combating infectious diseases and cancer, the company leverages its proprietary PIKA immunomodulating technology platform. This platform supports the development of innovative products such as the PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001, targeting various critical medical needs.
Operating across multiple global markets including China, the United States, Singapore, the United Arab Emirates, and the Philippines, LakeShore Biopharma is dedicated to expanding access to its advanced biopharmaceutical solutions. Formerly known as YS Biopharma Co., Ltd., the company rebranded as LakeShore Biopharma Co., Ltd. in May 2024, reflecting its evolution and commitment to advancing healthcare through groundbreaking research and development initiatives.
Founded in 2002 and headquartered in Beijing, China, LakeShore Biopharma continues to drive innovation in the biopharmaceutical sector. With a strong foundation in scientific excellence and strategic global presence, the company is poised to make significant strides in improving public health outcomes worldwide.